Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - DIA Presentation 2008
•
13 gefällt mir•3,663 views
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
![Session Panel ,[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Empfohlen
Empfohlen
Weitere ähnliche Inhalte
Was ist angesagt?
Was ist angesagt? (20)
Andere mochten auch
Andere mochten auch (12)
Ähnlich wie Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - DIA Presentation 2008
Ähnlich wie Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - DIA Presentation 2008 (20)
Mehr von Yavuz Silay
Mehr von Yavuz Silay (6)
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - DIA Presentation 2008
- 1. New Strategies for Successful Licensing Acquisitions Peter McFarland, PharmD Postdoctoral Fellow, Clinical Development Forest Labs, Inc. / St. John’s University
- 7. Identifying Licensing Opportunities Aaron Pelta, MBA Senior Manager, Corporate Development Cubist Pharmaceuticals
- 15. Where Do You Find It? Quality Your Network Banks Finders Management Venture Capital Conferences Publications Databases Academia Unsolicited
- 17. One Winning Approach Most Attractive (Most Likely) No Value No Value Accurate Inaccurate Consensus Non-Consensus No Value
- 18. Identifying Opportunities Scientific Assessment Identifying Opportunities Scientific Assessment Deal Finalization
- 19. Strategies for Conducting New Product Scientific Assessment (Due Diligence) Yavuz S. Silay, MD,CCRP Associate Director of Clinical Science, Clinical and Medical Affairs KV Pharmaceutical, Ther-Rx and Ethex Corporations
- 21. Overview of the Licensing Process Out-licensing In-licensing Source: MedTRACK, Sept ’07. Datamonitor Identification of the company’s limitations, and what is required to overcome these Identification of what products can be licensed and to who Performing evaluations Identification of gaps in the portfolio; Assessment of what it can offer as a partner? Evaluation of needs and identification of potential candidates Signing confidentiality agreements, drawing-up term sheets, due diligence Licensing Strategy Identifying Opportunity Licensing Evaluations Finalizing the Deal and Alliance Management
- 22. What therapeutic areas are more popular? Recent trends? CNS 15% Other 12% Infections 15% Cardiovascular 12% AIID 10% Cancer 7% Women’s Health 7% Digestive System 5% Multiple 4% Respiratory 5% Blood 4% Metabolic/Endocrinology 4% Marketing and Promotion Deals by therapy area, 2005-06 Source: MedTRACK, Sept ’07, Datamonitor
- 32. Factors leading to partnership breakdown during licensing deals
- 33. Key Elements
- 34. Key Factors
- 37. Scientific Assessment Deal Finalization Identifying Opportunities Scientific Assessment Deal Finalization
- 38. Alliance Management & Finalizing the Deal Raj Riswadkar Sr. Director Business Enterprise Development K V Pharmaceutical
- 51. Identifying Opportunities Scientific Assessment Deal Finalization Successful License Acquisition
Hinweis der Redaktion
- I’d like to welcome everyone the session. This session is entitled “New Strategies for Successful Licensing Acquisitions.” Please take a moment to silence an electronic devices you may be carrying and to get yourselves situated. Also, if you’ve just realized that you’ve ventured into the wrong room, please use this time to exit the room if need be….(2mintues). Excellent! Well it looks like most everyone who is attending the session has had a chance to settle in, so I’d like to get started. Again, I would like to welcome everyone and thank you for attending the session today. . . I’m glade you all could make it. My name is Peter McFarland. I am a PharmD Fellow at Forest Labs, Inc. and St. John’s University. I’ve been with a fellow in Clinical Development with Forest for about one year now, and one of the most intriguing aspects that I’ve noticed about the company is that they license all of their products from other companies. Now being able to see and experience this type of R&D first hand has been a great introduction into the aspects of product in-licensing, but what it has really done is sparked my interest into finding out more about the strategies that go into product licensing…. and how do we get the right products at the right time, that fit our corporate strategy? (NEXT SLIDE)